Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Merger Synergies | Explore how Neuronetics' merger with Greenbrook TMS is reshaping its market position, with projected revenue of $145 million in 2023 and anticipated cost savings of $22 million |
Financial Trajectory | Delve into Neuronetics' path to profitability, with analysts projecting positive adjusted EBITDA and cash flow by fiscal year 2025, driven by merger synergies |
Market Expansion | Learn about Neuronetics' strategies to increase its total addressable market by 35% through new clinical indications, including therapies for adolescents |
Investment Outlook | Analyst price targets for Neuronetics range from $5.50 to $8.00, reflecting varied perspectives on the company's growth potential and market challenges |
Metrics to compare | STIM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSTIMPeersSector | |
---|---|---|---|---|
P/E Ratio | −5.4x | −3.5x | −0.5x | |
PEG Ratio | −0.65 | −0.20 | 0.00 | |
Price/Book | 9.8x | 3.2x | 2.6x | |
Price / LTM Sales | 2.4x | 3.4x | 3.3x | |
Upside (Analyst Target) | 64.9% | 27.2% | 43.5% | |
Fair Value Upside | Unlock | 5.6% | 6.9% | Unlock |